Drug Approval | June 26, 2026
Merck wins EU nod for KEYTRUDA-Padcev regimen in muscle-invasive bladder cancer
The approval is based on results from the pivotal Phase 3 KEYNOTE-905 trial
The approval is based on results from the pivotal Phase 3 KEYNOTE-905 trial
Karkinos’ model aims to close both gaps by combining World Health Organization-recommended HPV DNA testing with a digitally enabled continuum of care
Centessa is a clinical-stage biotech focused on developing orexin receptor 2 agonists
Over the course of his career, he has also held leadership roles at Pfizer, Alembic Pharmaceuticals, and Cipla
Health ministry notifies amendments to the Drugs Rules, 1945 to expand the ambit of Schedule H2 and bring additional categories of drugs under the QR Code-based track and trace framework
In his new role, he will lead the company's growth strategy across Africa, strengthen healthcare partnerships, and expand access to innovative diagnostic solutions
Backed by Phase 3 trial showing 24% lower risk of progression
Partnership with Sunshine Healthcare aims to build local pharmaceutical capabilities and strengthen supply chain resilience
Experts announce upcoming Amyotrophic lateral sclerosis (ALS) studies, advocate early diagnosis, comprehensive care, and stronger support systems for patients and caregivers
Acquisition strengthens Merck's life sciences portfolio, expands capabilities across research and biopharma manufacturing
Subscribe To Our Newsletter & Stay Updated
